Your browser doesn't support javascript.
loading
Analyzing breast cancer invasive disease event classification through explainable artificial intelligence.
Massafra, Raffaella; Fanizzi, Annarita; Amoroso, Nicola; Bove, Samantha; Comes, Maria Colomba; Pomarico, Domenico; Didonna, Vittorio; Diotaiuti, Sergio; Galati, Luisa; Giotta, Francesco; La Forgia, Daniele; Latorre, Agnese; Lombardi, Angela; Nardone, Annalisa; Pastena, Maria Irene; Ressa, Cosmo Maurizio; Rinaldi, Lucia; Tamborra, Pasquale; Zito, Alfredo; Paradiso, Angelo Virgilio; Bellotti, Roberto; Lorusso, Vito.
Affiliation
  • Massafra R; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Fanizzi A; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Amoroso N; INFN, Sezione di Bari, Bari, Italy.
  • Bove S; Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari Aldo Moro, Bari, Italy.
  • Comes MC; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Pomarico D; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Didonna V; INFN, Sezione di Bari, Bari, Italy.
  • Diotaiuti S; Dipartimento di Fisica, Università degli Studi di Bari Aldo Moro, Bari, Italy.
  • Galati L; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Giotta F; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • La Forgia D; International Agency for Research on Cancer, Lyon, France.
  • Latorre A; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Lombardi A; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Nardone A; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Pastena MI; Dipartimento di Ingegneria Elettrica e dell'Informazione, Politecnico di Bari, Bari, Italy.
  • Ressa CM; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Rinaldi L; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Tamborra P; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Zito A; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Paradiso AV; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Bellotti R; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Lorusso V; IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
Front Med (Lausanne) ; 10: 1116354, 2023.
Article in En | MEDLINE | ID: mdl-36817766
ABSTRACT

Introduction:

Recently, accurate machine learning and deep learning approaches have been dedicated to the investigation of breast cancer invasive disease events (IDEs), such as recurrence, contralateral and second cancers. However, such approaches are poorly interpretable.

Methods:

Thus, we designed an Explainable Artificial Intelligence (XAI) framework to investigate IDEs within a cohort of 486 breast cancer patients enrolled at IRCCS Istituto Tumori "Giovanni Paolo II" in Bari, Italy. Using Shapley values, we determined the IDE driving features according to two periods, often adopted in clinical practice, of 5 and 10 years from the first tumor diagnosis.

Results:

Age, tumor diameter, surgery type, and multiplicity are predominant within the 5-year frame, while therapy-related features, including hormone, chemotherapy schemes and lymphovascular invasion, dominate the 10-year IDE prediction. Estrogen Receptor (ER), proliferation marker Ki67 and metastatic lymph nodes affect both frames.

Discussion:

Thus, our framework aims at shortening the distance between AI and clinical practice.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Med (Lausanne) Year: 2023 Document type: Article Affiliation country: Italy

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Front Med (Lausanne) Year: 2023 Document type: Article Affiliation country: Italy